Q-omics provides the consensus-scored PTDSS1 profile across patient tissues and cancer cell-line models. PTDSS1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, PTDSS1 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, PTDSS1 RNA expression shows 18,836 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KICH, HNSC, and ACC as cancer lineages where PTDSS1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PTDSS1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PTDSS1 survival associations across molecular data types. PTDSS1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PTDSS1 RNA expression–survival associations across cancer types. High PTDSS1 expression shows unfavorable associations in KICH, UVM, LIHC, HNSC, ACC and LGG. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for PTDSS1 RNA expression.
This table summarizes PTDSS1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PTDSS1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PTDSS1 shows higher tumor expression in HNSC, COAD, BLCA, STAD, LIHC and LUSC. The HNSC box plot shows higher PTDSS1 RNA expression in tumor versus normal tissue (log2 FC = +1.477, t-test p < 0.001).
This table shows molecular features associated with PTDSS1 in patient tissues and cancer cell lines. In patient samples, PTDSS1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, PTDSS1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and UPPER_AERODIGESTIVE_TRACT.
